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Objectives. This study evaluates the clinical efficacy of d,l-
sotalol in patients with sustained ventricular tachyarrhythmias.
Background. D,l-sotalol is an important antiarrhythmic agent to
prevent recurrences of sustained ventricular tachyarrhythmias (VT/
VF). However, evidence is lacking that an antiarrhythmic agent like
d,l-sotalol can reduce the incidence of sustained ventricular tachyar-
rhythmias in comparison to no antiarrhythmic drug treatment.
Methods. A prospective study was performed in 146 consecutive
patients with inducible sustained ventricular tachycardia or ven-
tricular fibrillation. In 53 patients, oral d,l-sotalol prevented induc-
tion of VT/VF during electrophysiological testing and patients were
discharged on oral d,l-sotalol (sotalol group). In 93 patients, VT/VF
remained inducible and a defibrillator (ICD) was implanted. After
implantation of the device patients were randomly assigned to oral
treatment with d,l-sotalol (ICD/sotalol group, n 5 46) or no antiar-
rhythmic medication (n 5 47, ICD-only group).
Results. During follow-up, 25 patients (53.2%) in the ICD-only
group had a VT/VF recurrence in comparison to 15 patients
(28.3%) in the sotalol group and 15 patients (32.6%) in the
ICD/sotalol group (p 5 0.0013). Therapy with d,l-sotalol, amio-
darone or metoprolol was instituted in 12 patients (25.5%) of the
ICD-only group due to frequent VT/VF recurrences or symptom-
atic supraventricular tachyarrhythmias. In nine patients, 17% of
the sotalol group, an ICD was implanted after VT/VF recurrence,
three patients (5.7%) received amiodarone. Total mortality was
not different between the three groups.
Conclusions. D,l-sotalol significantly reduces the incidence of
recurrences of sustained ventricular tachyarrhythmias in compar-
ison to no antiarrhythmic drug treatment.
(J Am Coll Cardiol 1999;33:46–52)
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D,l-sotalol is a beta-adrenergic blocking drug with class 3
antiarrhythmic properties (1). Since the results of the CAST
and the ESVEM study were published, d,l-sotalol has become
one of the most important drugs for the treatment of sustained
ventricular tachyarrhythmias (2–5). However, it is unknown
whether the clinical efficacy of d,l-sotalol in patients with
life-threatening sustained ventricular tachyarrhythmias can be
predicted by programmed electrical stimulation. The efficacy
of d,l-sotalol in preventing stimulation-induced arrhythmias
may be due to its class 3 antiarrhythmic activity (6–9). How-
ever, the prevention of a spontaneous recurrence of a sus-
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tained ventricular tachycardia or ventricular fibrillation may
however be related to its beta-blocking effects. Data from the
ESVEM study suggest that the clinical efficacy of d,l-sotalol
with programmed electrical stimulation is underestimated (4).
One nonrandomized open study compared the clinical efficacy
of d,l-sotalol in patients with sustained ventricular tachyar-
rhythmias. It turned out that neither the response to pro-
grammed electrical stimulation nor the response of spontane-
ous arrhythmias to oral d,l-sotalol during 24 h Holter
monitoring predicted the clinical efficacy of the compound
during follow-up (10,11). Therefore, current data on d,l-sotalol
emphasize that the clinical efficacy of d,l-sotalol may be
substantially different from what is seen during electrophysio-
logical testing (5,12).
The major problem with antiarrhythmic drug studies in
patients with life-threatening ventricular tachyarrhythmias is
the lack of a control group for ethical reasons. Furthermore,
several studies suggest that persisting inducibility is associated
with a poor prognosis (13). Therefore, we believe that despite
inefficacy during electrophysiological testing, treatment with
an antiarrhythmic drug cannot be justified. However, in pa-
tients with an implantable cardioverter defibrillator, antiar-
rhythmic therapy is not mandatory and even if it fails the
arrhythmia will be terminated by the implanted device. Therefore
we conducted a prospective randomized study with d,l-sotalol in
patients with sustained ventricular tachyarrhythmias and an im-
plantable cardioverter defibrillator to elucidate the clinical effi-
cacy of d,l-sotalol in comparison to no antiarrhythmic medication.
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Methods
This is an open labelled, prospective, randomized study in
patients with organic heart disease and unstable symptomatic
sustained ventricular tachycardia or aborted sudden cardiac
death.
Patient selection. From January 1988 to December 1995,
432 consecutive patients with sustained ventricular tachycardia
or aborted sudden death were seen in our department. The
inclusion criteria were: 1) symptomatic sustained ventricular
tachycardia or ventricular fibrillation in the presence of organic
heart disease, not associated with an acute event like myocar-
dial infarction, electrolyte disturbance etc.; 2) inducible sus-
tained ventricular tachyarrhythmia; 3) no contraindications to
treatment with beta-adrenergic blocking drugs; 4) no contra-
indications to treatment with an implantable cardioverter
defibrillator (ICD); 5) tolerance of d,l-sotalol during in hospi-
tal treatment; and 6) no prior treatment with amiodarone. 286
patients (66.2%) were excluded from participation in the study.
The reasons for exclusion were as follows: 25 patients were
excluded during the initial phase of the study, because they had
nonsyncopal sustained ventricular tachycardia. At that time,
implantation of an ICD seemed not appropriate in nonsynco-
pal ventricular tachycardia. Twenty-five patients received elec-
trophysiologicaly guided antitachycardia surgery or catheter
ablation as the initial therapy because they had frequent
episodes of hemodynamically tolerated ventricular tachycar-
dia. In 136 patients, overall prognosis was limited, due to old
age, advanced heart disease, or severe concomitant disease and
ICD therapy was not thought to be appropriate. Contraindi-
cations to therapy with betablocking agents (mainly chronic
obstructive pulmonary disease) was present in 61 patients. In
21 patients, the index arrhythmic event occurred during treat-
ment with class 1 or class 3 antiarrhythmic drugs; 75 patients
had received amiodarone prior to admission to our hospital.
Forty-seven patients had incessant ventricular tachycardia or
frequent episodes of nonsustained and/or sustained ventricular
tachycardia and antiarrhythmic therapy seemed to be manda-
tory. Forty-one patients had sustained ventricular tachycardia
without structural heart disease. ICD therapy seemed not to be
appropriate in these patients due to the excellent prognosis of
patients with idiopathic ventricular tachycardia (14). In 31
patients, no arrhythmia was induced during programmed elec-
trical stimulation, 21 patients declined ICD implantation or
electrophysiological testing, 11 patients did not tolerate d,l-
sotalol or developed torsades de pointes during the initial
treatment phase. In about one third of the patients, more than
one criterion led to exclusion from the study. Finally, 146
patients (128 men and 18 women, 33.8% of the total popula-
tion seen at our department) aged 21 to 72 years (64 6 13
years) with inducible sustained ventricular tachycardia (n 5
105, 71.9%) or inducible ventricular fibrillation (n 5 41,
28.1%) were included in the study and followed for at least one
year. Inducible ventricular fibrillation was accepted as an
arrhythmia of clinical relevance in patients with aborted sud-
den death. The arrhythmia history was symptomatic sustained
monomorphic ventricular tachycardia in 94 patients (64.4%)
and cardiac arrest in 52 patients (35.6%). The characteristics of
the patients evaluated are listed in Table 1. All patients
received coronary angiography and 138 patients (94.5%) had a
Abbreviations and Acronyms
VT/VF 5 sustained ventricular tachyarrhythmias
ICD 5 implantable cardioverter defibrillator
Table 1. Patient Characteristics
D,l-sotalol (n 5 53) ICD/d,l-sotalol (n 5 46) ICD (n 5 47) p value
Age (years) 61 6 16 59 6 18 64 6 17 0.36
gender 7/ (13.2%), 46? (86.8%) 6/ (13%), 40? (87%) 5/ (10.6%), 42? (89.4%) 0.91
Cardiac disease
CAD n 5 39 (73.6%) n 5 31 (67.4%) n 5 28 (59.6%) 0.64
DCM n 5 11 (20.7%) n 5 13 (28.3%) n 5 16 (34%)
other n 5 3 (5.7%) n 5 2 (4.3%) n 5 3 (6.4%)
Functional status
NYHA I/II n 5 44 (83%) n 5 39 (84.8%) n 5 41 (87.2%) 0.84
NYHA III n 5 9 (17%) n 5 7 (15.2%) n 5 6 (12.8%)
Left ventricular EF, % 37 6 17% 35 6 18% 38 6 19% 0.72
Presenting arrhythmia
VT VT n 5 38 (71.7%) VT n 5 26 (56.5%) VT n 5 30 (63.8%) 0.29
Sudden cardiac death SD n 5 15 (28.3%) SD n 5 20 (43.5%) SD n 5 17 (36.2%)
VT cycle length (ms)*) 304 6 32 ms (n 5 19) 298 6 34 ms (n 5 14) 321 6 44 ms (n 5 15) 0.23
Inducible arrhythmia
VT n 5 42 (79.2%) n 5 32 (70%) n 5 31 (66%) 0.31
VF n 5 11 (20.8%) n 5 14 (30%) n 5 16 (34%)
VT cycle length 287 6 31 ms 281 6 42 ms 279 6 32 ms 0.59
CAD 5 coronary artery disease; DCM 5 dilative cardiomyopathy; VT 5 ventricular tachycardia; VF 5 ventricular
fibrillation; SD 5 sudden death; EF 5 ejection fraction. *)Only patients in whom an ECG with the spontaneous
tachycardia was available.
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left ventricular angiogram. The majority of patients had coro-
nary artery disease (n 5 98, 67.1%) or dilated cardiomyopathy
(n 5 40, 27.4%). Left ventricular ejection fraction was de-
pressed (,45%) in 123 patients (84.2%) and ranged from 13%
to 65% (37 6 19%). For termination of prior antiarrhythmic
medication or treatment with d,l-sotalol, patients were admit-
ted to the coronary care unit or the intensive care unit. All
antiarrhythmic drugs were discontinued for five elimination
half-lives before entry into the study.
Study protocol. In patients with sustained ventricular
tachycardia or aborted sudden death whose arrhythmia could
be induced by programmed ventricular stimulation, the efficacy
of oral d,l-sotalol in preventing stimulation-induced sustained
ventricular tachyarrhythmias was investigated. If the arrhyth-
mia was rendered noninducible by d,l-sotalol, the patient was
discharged and followed on an outpatient basis (sotalol group).
If the arrhythmia remained inducible, the patient received an
ICD. Before implantation of the device, the patient was
randomized to open label treatment with d,l-sotalol (ICD/
sotalol group) or to no antiarrhythmic drug treatment (ICD-
only group). Again patients were followed on an outpatient
basis. All patients were followed up for at least one year. The
primary end point was the recurrence of arrhythmias (ventric-
ular tachycardia, ventricular fibrillation, or sudden death) and
the time to arrhythmia recurrence in our three patient groups.
Secondary end points were drug tolerance and total mortality.
Informed consent was obtained from all patients, the study
protocol was approved by the local ethical committee.
Electrophysiological study. Programmed ventricular stim-
ulation with up to three extrastimuli at four basic drive cycle
lengths (500 ms, 430 ms, 375 ms, and 330 ms) was performed
in all patients. If necessary, the ventricular stimulation protocol
was repeated with a catheter placed in the right ventricular
outflow tract. The end point of our ventricular stimulation
protocol was reproducible (twice) induction of the clinical
arrhythmia, i.e., sustained ventricular tachycardia in patients
with a history of sustained ventricular tachycardia or aborted
sudden death or induction of ventricular fibrillation in patients
with aborted sudden death.
Oral d,l-sotalol administration. All patients received
80 mg d,l-sotalol as the initial daily dose. If tolerated, the dose
was increased in steps of 80 mg per 24 h up to 400 mg per 24 h.
Tolerance of d,l-sotalol was judged on clinical criteria such as
dizziness, development of congestive heart failure or sponta-
neous recurrence of ventricular tachyarrhythmias.
Efficacy criteria of electrophysiological testing. Patients
undergoing electrophysiological study while receiving oral
d,l-sotalol were studied at steady state after receiving a stable
dose for at least 72 h. The ventricular stimulation protocol and
the end points were identical to those used in the baseline
investigation. Only complete suppression of inducible nonsus-
tained or sustained ventricular tachyarrhythmias was accepted
as success. Patients in whom the ventricular tachyarrhythmia
remained inducible despite oral application of oral d,l-sotalol
received an ICD.
Randomized sotalol treatment in ICD recipients. After
recovery from implantation of the device patients received
randomized oral treatment with d,l-sotalol or no antiarrhyth-
mic treatment. If necessary, patients in the ICD-only arm
received metoprolol for control of sinus tachycardia. Oral
verapamil in combination with digoxin was prescribed in
patients with chronic or paroxysmal atrial fibrillation.
Ventricular arrhythmias occurring in the first week after
implantation of the device were disregarded in analysis, since
they might be mainly related to the implantation procedure
itself (15,16).
Follow-up and definition of end points. Patients with an
ICD were seen on an outpatient basis every three months.
Patients in the sotalol group were seen at least twice in a year,
or the well-being of the patient and adherence to the therapy
was confirmed by a telephone call to the patient’s private
practitioner (n 5 2).
End points of our study protocol were as follows: 1)
Recurrence of ventricular tachycardia or ventricular fibrilla-
tion after discharge from hospital: in patients with oral d,l-
sotalol, a recurrence of ventricular tachycardia was defined as
spontaneous sustained ventricular tachycardia, or syncope, or
aborted sudden death or sudden death. In patients with an
ICD, a recurrence of ventricular tachycardia or ventricular
fibrillation was defined as a symptomatic (palpitations, dizzi-
ness, syncope) arrhythmic event followed by an intervention of
the ICD. Appropriateness of ICD therapy was verified inde-
pendently by two cardiologists experienced in ICD therapy
(V.K. and C.M.). 2) Intolerance of the treatment with d,l-
sotalol, i.e. overt cardiac failure, symptomatic hypotension or
bradycardia. 3) Death: A time-based definition of sudden
death was used. Sudden death, i.e. death within one hour after
the occurrence of symptoms (17). Sudden death was assumed
to be an arrhythmic death even if no intervention of the ICD
was stored at the presumed time of death. Cardiac death, i.e.
death of cardiac origin, not fulfilling the criteria for sudden
cardiac death (17). Noncardiac death, i.e. death not primarily
due to cardiac causes (17).
Data analysis. The statistics package of JMP Version
3.1.6.2. (SAS Institute, Cary, North Carolina) was used for data
analysis. Paired data before and after application of d,l-sotalol
were analyzed using the paired t test, for comparison of more
than two groups the one way ANOVA test (with post test if the
p value was ,0.05) was used. All values are expressed as
mean 6 1 standard deviation. Group comparison was done
using the Chi-square test and applying Yates correction were
appropriate. Survival fractions were calculated using the
Kaplan–Meier method, survival curves were compared by the
log-rank method. All analysis were performed on the intention
to treat basis.
Results
Patient characteristics and baseline electrophysiological
findings (Table 1). There were no significant differences in the
clinical presentation of patients in whom d,l-sotalol suppressed
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the arrhythmia and patients in whom the arrhythmia remained
inducible.
In the baseline electrophysiological study, a sustained
monomorphic ventricular tachycardia was inducible in 105
patients. In 41 patients ventricular fibrillation was the only
inducible arrhythmia. Baseline electrophysiological character-
istics and type of induced arrhythmia were not different
between patients who responded to d,l-sotalol and those who
did not respond to the drug (Table 1).
Electrophysiological effects of oral d,l-sotalol. With the
oral d,l-sotalol treatment, a significant increase of sinus cycle
length (from 851 6 171 ms to 1045 6 178 ms), QT-interval
(from 388 6 39 ms to 453 6 50 ms), the effective refractory
period of the right ventricle (from 240 6 28 ms to 278 6
39 ms), and the cycle length of the ventricular tachycardia
(from 298 6 47 ms to 334 6 47 ms) was achieved. The
electrophysiological effects of d,l-sotalol and the daily oral
dose of d,l-sotalol were not different between patients in whom
the arrhythmia was rendered noninducible and patients in
whom the arrhythmia remained inducible. In 53 patients
(36.3%), complete suppression of inducible sustained or non-
sustained ventricular tachyarrhythmias was achieved (d,l-
sotalol 330 6 89 mg/day).
ICD therapy. In 93 patients (63.7%) d,l-sotalol (348 6
78 mg per day) did not suppress inducible sustained ventricular
tachyarrhythmias, and an ICD was implanted. The first seven
patients received an epicardial lead system, thereafter only
transvenous lead systems were used. Due to the rapid change
in ICD technology, different types of devices were implanted.
The use of transvenous lead systems, devices with biphasic
shock capability, antitachycardia pacing and stored electrocar-
diograms was not significantly different between the two
groups. 83.8% had a device capable of storing electrograms.
Long term efficacy of d,l-sotalol. A complete follow-up is
available for all patients included in the study. Follow-up
duration is not different between the three study groups.
In the sotalol group, 12 patients (22.6%) had a recurrence
of sustained symptomatic ventricular tachycardia (n 5 10) or
ventricular fibrillation (n 5 2). One female patient developed
recurrent syncope with documented torsades de pointes after
an otherwise uneventful followup of almost two years. Six
patients (11.3%) died during follow-up in the sotalol group,
two patients died suddenly (Fig. 1 and 2). Hence, 15 patients
(28.3%) out of 53 patients reached a primary end point.
In the ICD/sotalol group, 14 patients (30.4%) had a recur-
rence of the ventricular tachycardia (n 5 9, 19.6%) or ventric-
ular fibrillation (n 5 5, 10.9%), in all cases successfully
terminated by the device. Multiple shocks provoked by recur-
rent torsades de pointes were seen in one patient, who did not
have a recurrence of his baseline arrhythmia. Incessant ven-
tricular tachycardia was observed in a further patient. There-
fore 15 patients (32.6%) out of 46 patients had reached the
primary end point.
In the ICD-only group, 24 patients (51.1%) had a recur-
rence of ventricular tachycardia (n 5 17, 36.2%) or ventricular
fibrillation (n 5 7, 14.9%). One patient suddenly died, unwit-
nessed, at home. The ICD had terminated rapid ventricular
tachycardia on the evening before (about 12 h before) this
death, no stored electrogram is available at the presumed time
of death. Therefore, in the ICD-only group 25 patients (53.2%)
out of 47 patients had ventricular tachycardia, ventricular
fibrillation or sudden death during follow-up.
The recurrence rate was significantly different between the
ICD-only group and the sotalol group (p 5 0.0008) and the
ICD-only versus ICD/sotalol group (p 5 0.023, Fig. 1). There
was no difference between the sotalol group and the ICD/
sotalol group (p 5 0.288).
Figure 1. Life-table curves for recurrence of ventricular tachycardia or
ventricular fibrillation in the three study groups. Recurrences were
significantly more frequent in patients of the ICD-only group in
comparison to the Sotalol group (p 5 0.0008) and the ICD/sotalol
group (p 5 0.023). There was no significant difference between the
sotalol group and the ICD/sotalol group (p 5 0.288). Two patients in
the sotalol group and one patient in the ICD group died suddenly and
in all three patients this was the first recurrence of ventricular
tachyarrhythmias (see methods for the definition of a recurrence of
ventricular tachycardia or ventricular fibrillation).
Figure 2. Total mortality was not different between the three study
groups (sotalol group versus ICD group p 5 0.623, sotalol group versus
ICD/sotalol group p 5 0.9, ICD group versus ICD/sotalol group p 5
0.63). In the sotalol group and the ICD/sotalol group two patients died
suddenly respectively, in the ICD group one patient died suddenly.
Minimum value on the y-axis is 50%! (see methods for the definition
of sudden death, cardiac death and noncardiac death).
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Total mortality (Figure 2). Total mortality was not differ-
ent between the three groups. In the sotalol only group, two
patients died suddenly, one patient died from progressive heart
failure and one patient from recurrent myocardial infarction.
In the ICD/sotalol group four patients (8.7%) died, two
patients died suddenly. In both patients, only R-R intervals
from the ICD were available. In one of these two patients, four
episodes of ventricular fibrillation within one hour were ter-
minated by the ICD, a fifth episode was not terminated by five
consecutive 34J monophasic shocks. In the second patient,
ventricular fibrillation was probably terminated with the sec-
ond 34J shock. However the patient died instantaneously.
Autopsy was declined in both patients. One patient died from
heart failure.
In the ICD-only group, two patients died from pump failure
and one after a recurrent myocardial infarction. One patient
had autopsy-proven lethal pulmonary embolism seven days
after implantation of an ICD with a transvenous lead system.
Tolerance of d,l-sotalol. In the sotalol group, the drug had
to be withdrawn in three patients due to hemodynamic intol-
erance or bradycardia. A reduction of the prescribed oral dose
of d,l-sotalol by the patient or the private practitioner was
noted in five patients. However, only one had a recurrence of
sustained ventricular tachycardia.
Significant bradycardia and hypotension led to discontinu-
ation of d,l-sotalol in two patients of the ICD/sotalol group. In
two further patients, the dose of oral d,l-sotalol was decreased
by the patient.
Change of therapy. An ICD was implanted in nine patients
due to symptomatic sustained ventricular tachyarrhythmias
(VT/VF) recurrence (including the female patient with tor-
sades de pointes) or recurrent aborted sudden death in the
sotalol group. Three patients switched to amiodarone. There-
fore, a change of therapy was necessary in 12 patients (22.6%).
A change of therapy was necessary in two patients (4.3%) in
the ICD/sotalol group. In the patient with torsade des pointes,
d,l-sotalol was withdrawn, one patient with frequent recur-
rences of ventricular tachycardia switched to amiodarone.
A change of therapy was necessary in 12 patients (25.5%) in
the ICD-only group. Therapy with d,l-sotalol was instituted in
five patients. Due to frequent recurrences of sustained ventric-
ular tachycardia, six patients were treated with metoprolol for
supraventricular arrhythmias and one patient received amio-
darone for control of ventricular arrhythmias. The need for a
change of the treatment regimen was significantly (p 5 0.0047)
different between the three study groups.
Discussion
The main findings of our study are: recurrences of sustained
ventricular tachyarrhythmias were significantly reduced by
d,l-sotalol in comparison to no antiarrhythmic drug treatment.
So-called responders and nonresponders to d,l-sotalol during
programmed electrical stimulation have a comparable inci-
dence of recurrences of ventricular tachyarrhythmias during
follow-up (Fig. 1).
Clinical efficacy of d,l-sotalol. The present study is the first
one comparing the clinical efficacy of d,l-sotalol in responders
and nonresponders during electrophysiological testing to an
untreated patient group. D,l-sotalol, even if ineffective during
electrophysiological testing, turned out to be superior in terms
of arrhythmia suppression in comparison to no antiarrhythmic
treatment during long term follow-up. We therefore recom-
mend treatment with d,l-sotalol in patients with an ICD to
reduce the number of therapies delivered by the device.
Similar reports have been published, showing that betablocker
treatment decreases the relative risk of receiving a shock by the
ICD (18). It is, however, contrary to a study with various class
1 and class 3 antiarrhythmic agents, that could not find any
benefit of adjunctive antiarrhythmic therapy in patients with an
ICD (19).
Since the introduction of parallel testing by Brugada and
Wellens, it is well known that the clinical efficacy of an
antiarrhythmic drug may differ from what is seen during
programmed electrical stimulation (20,21). With amiodarone,
it has been shown that the clinical efficacy may be higher than
would have been predicted by the results of programmed
electrical stimulation (22–24). Like d,l-sotalol, amiodarone is
not a pure class 3 antiarrhythmic drug and its clinical efficacy
cannot be explained by its antiarrhythmic effects only (12,25).
In the ESVEM trial d,l-sotalol was more effective during follow
up than various class 1 antiarrhythmic drugs, although electro-
physiological testing and Holter monitoring would have pre-
dicted a similar efficacy. This finding supports our theory that
the clinical efficacy of a complex compound like d,l-sotalol
cannot be predicted by electrophysiological testing. Empirical
treatment with d,l-sotalol might lead to results comparable to
those obtained with amiodarone (26). In one uncontrolled
trial, neither the response to Holter monitoring nor the
response to programmed electrical stimulation predicted the
clinical efficacy of d,l-sotalol (11). One recent study suggests
that programmed electrical stimulation is useful in predicting
the efficacy of sotalol therapy (27). However, the group of
patients treated with sotalol, despite inefficacy of the drug
during the electrophysiological study, is small.
Value and shortcomings of programmed electrical stimu-
lation. The recurrence of sustained ventricular tachycardia or
ventricular fibrillation was not significantly different between
patients in whom d,l-sotalol prevented induction of a VT/VF
and patients in whom d,l-sotalol failed to prevent reinduction
of a sustained ventricular tachyarrhythmia. Hence, electro-
physiological testing underestimates the clinical efficacy of the
drug. Similar data have been obtained with nadolol in patients
with sustained ventricular tachycardia (28). However, a much
larger patient population is necessary to prove our hypothesis
that electrophysiologic testing is not useful for prediction of
efficacy in the case of d,l-sotalol.
In our study, about one third of the patient population in
the sotalol-only group had a recurrence of VT/VFs despite a
positive (i.e., suppression of sustained ventricular arrhythmias)
result of electrophysiological testing. This is in contrast with
many studies reporting a low risk for recurrence of ventricular
50 KU¨HLKAMP ET AL. JACC Vol. 33, No. 1
CLINICAL EFFICACY OF d,l-SOTALOL January 1999:46–52
tachycardia or ventricular fibrillation if the arrhythmia is not
inducible (7–9,29–32). However, in most of these studies, a
limited number of patients are treated for a short period of
time and a control group is lacking in all studies.
There may be several reasons why the response to pro-
grammed electrical stimulation fails to predict the clinical
efficacy of d,l-sotalol: day to day variability in induction of
VT/VF varies, especially if induction of the arrhythmia re-
quires stimulation with more than two extrastimuli and multi-
ple sites (33,34).
Another important point is that, during programmed elec-
trical stimulation, the class 3 effects of d,l-sotalol on the reentry
circuit are mainly tested since it has been shown that a pure
betablocker does not change inducibility during programmed
electrical stimulation (35,36). However, the reentry circuit in
sustained ventricular tachycardia is not a fixed anatomic circuit
but is amenable to changes in autonomic tone, electrolyte
disturbances, stretch, ischemia, and not least, varying levels of
the antiarrhythmic drug itself. Beta-blockade interacts with the
autonomic nervous system (37), increases the fibrillation
threshold (38) and reduces ischemia (39), factors which might
trigger the induction of VT/VF (36). The importance of these
effects cannot be assessed by programmed electrical stimula-
tion. Therefore not only the results of the baseline study vary,
the same is true for the electrophysiological study on antiar-
rhythmic drugs (33). We recently performed programmed
electrical stimulation in patients, in whom d,l-sotalol prevented
induction of a sustained ventricular tachyarrhythmia after a
mean follow-up of 14 6 10 months. In 42% of patients, the
initial arrhythmia was induced despite the fact that the patient
had no spontaneous recurrence of the arrhythmia and the
clinical situation had not changed (40).
Prognostic influence of the cardioverter defibrillator. This
study is not designed to evaluate the effect of different thera-
peutic interventions on total mortality. Furthermore, the pa-
tient group is highly selected with about two thirds of the
patients having symptomatic ventricular tachycardia. Although
our numbers are small, our study does not support an approach
using an ICD in all patients with sustained ventricular tachy-
arrhythmias as first line therapy (41,42). However, 9 out of 53
patients (17%) in the sotalol-only group switched to ICD
therapy, because they had a symptomatic recurrence during
treatment with sotalol. The recently published AVID trial
showed that ICD therapy is superior to antiarrhythmic drug
therapy in prolonging survival among patients with life threat-
ening ventricular tachyarrhythmias (43).
Limitations of the study. Some uncertainty about arrhyth-
mia recurrences in our three study groups remains. In the
sotalol group only symptomatic recurrences could be docu-
mented, hence it is possible that we underestimated the true
incidence of recurrences in this group. On the other hand we
probably overestimate the number of recurrences in both ICD
arms. Some episodes might have terminated spontaneously or
symptomatic supraventricular tachycardia activated the device.
However, this should have occurred in similar frequency in
both ICD arms. There is indeed a larger number of recur-
rences in the ICD/sotalol group as compared to the sotalol-
only group. This difference is not significant. However, with the
number of patients included in our study, a difference of
clinical significance between responders to d,l-sotalol and
nonresponders to d,l-sotalol cannot be ruled out. A further
limitation is the dose of sotalol. A higher dose of sotalol might
have changed the clinical efficacy of the drug (27).
Finally, for further evaluation of the value of electrophysi-
ologic testing in the case of d,l-sotalol, a double blind study
comparing d,l-sotalol and placebo with an ICD as backup is
necessary in a much larger group of patients.
Conclusions. We conclude that d,l-sotalol is effective in
terms of arrhythmia suppression in comparison to no antiar-
rhythmic treatment even if it fails to prevent stimulation
induced ventricular tachyarrhythmias. Hence treatment with
d,l-sotalol in ICD patients is recommended to prevent recur-
rences of ventricular tachyarrhythmias. However, further stud-
ies are needed to finally learn the value or lack of electrophysi-
ologic testing.
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